Vannice K - Search Results

1

Success of program linking data sources to monitor H1N1 vaccine safety points to potential for even broader safety surveillance.

Salmon D, Yih WK, Lee G, Rosofsky R, Brown J, Vannice K, Tokars J, Roddy J, Ball R, Gellin B, Lurie N, Koh H, Platt R, Lieu T; PRISM Program Group. Salmon D, et al. Among authors: vannice k. Health Aff (Millwood). 2012 Nov;31(11):2518-27. doi: 10.1377/hlthaff.2012.0104. Health Aff (Millwood). 2012. PMID: 23129683

2

Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.

Salmon DA, Akhtar A, Mergler MJ, Vannice KS, Izurieta H, Ball R, Lee GM, Vellozzi C, Garman P, Cunningham F, Gellin B, Koh H, Lurie N; H1N1 Working Group of Federal Immunization Safety Task Force. Salmon DA, et al. Pediatrics. 2011 May;127 Suppl 1:S78-86. doi: 10.1542/peds.2010-1722L. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502251 Review.

3

Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines.

Black S, Eskola J, Siegrist CA, Halsey N, MacDonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C. Black S, et al. Among authors: vannice k. Lancet. 2009 Dec 19;374(9707):2115-2122. doi: 10.1016/S0140-6736(09)61877-8. Epub 2009 Oct 31. Lancet. 2009. PMID: 19880172 Free PMC article.

4

Attitudes and beliefs of parents concerned about vaccines: impact of timing of immunization information.

Vannice KS, Salmon DA, Shui I, Omer SB, Kissner J, Edwards KM, Sparks R, Dekker CL, Klein NP, Gust DA. Vannice KS, et al. Pediatrics. 2011 May;127 Suppl 1(Suppl 1):S120-6. doi: 10.1542/peds.2010-1722R. Epub 2011 Apr 18. Pediatrics. 2011. PMID: 21502250 Free PMC article.

5

Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.

Vannice KS, Keita M, Sow SO, Durbin AP, Omer SB, Moulton LH, Yaméogo TM, Zuber PL, Onwuchekwa U, Sacko M, Diomandé FV, Halsey NA. Vannice KS, et al. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S493-500. doi: 10.1093/cid/civ497. Clin Infect Dis. 2015. PMID: 26553680 Free PMC article.

6

The association between intentional delay of vaccine administration and timely childhood vaccination coverage.

Smith PJ, Humiston SG, Parnell T, Vannice KS, Salmon DA. Smith PJ, et al. Public Health Rep. 2010 Jul-Aug;125(4):534-41. doi: 10.1177/003335491012500408. Public Health Rep. 2010. PMID: 20597453 Free PMC article.

7

Clinical development and regulatory points for consideration for second-generation live attenuated dengue vaccines.

Vannice KS, Wilder-Smith A, Barrett ADT, Carrijo K, Cavaleri M, de Silva A, Durbin AP, Endy T, Harris E, Innis BL, Katzelnick LC, Smith PG, Sun W, Thomas SJ, Hombach J. Vannice KS, et al. Vaccine. 2018 Jun 7;36(24):3411-3417. doi: 10.1016/j.vaccine.2018.02.062. Epub 2018 Mar 7. Vaccine. 2018. PMID: 29525283 Free PMC article.

8

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.

Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, Milne G, Hladish TJ, Perkins TA, Cummings DA, Dorigatti I, Laydon DJ, España G, Kelso J, Longini I, Lourenco J, Pearson CA, Reiner RC, Mier-Y-Terán-Romero L, Vannice K, Ferguson N. Flasche S, et al. Among authors: vannice k. PLoS Med. 2016 Nov 29;13(11):e1002181. doi: 10.1371/journal.pmed.1002181. eCollection 2016 Nov. PLoS Med. 2016. PMID: 27898668 Free PMC article.

9

Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.

Wichmann O, Vannice K, Asturias EJ, de Albuquerque Luna EJ, Longini I, Lopez AL, Smith PG, Tissera H, Yoon IK, Hombach J. Wichmann O, et al. Among authors: vannice k. Vaccine. 2017 Oct 9;35(42):5535-5542. doi: 10.1016/j.vaccine.2017.08.066. Vaccine. 2017. PMID: 28893477 Free article. Review.

10

Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine.

Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, O'Brien K, Vannice K, Barrett A, Ferdinand E, Flasche S, Guzman M, Novaes HM, Ng LC, Smith PG, Tharmaphornpilas P, Yoon IK, Cravioto A, Farrar J, Nolan TM. Wilder-Smith A, et al. Among authors: vannice k. Lancet Infect Dis. 2019 Jan;19(1):e31-e38. doi: 10.1016/S1473-3099(18)30494-8. Epub 2018 Sep 5. Lancet Infect Dis. 2019. PMID: 30195995 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters